Swiss can­cer vac­cine biotech Nous­com rais­es $72M Se­ries C for PhII tri­als

Last year
Financing
Startups

Or­bital Ther­a­peu­tics clos­es South San Fran­cis­co lab, elim­i­nat­ing some roles

Last year
People
Startups

Ipsen, Gen­fit un­veil ad­di­tion­al PhI­II da­ta for rare liv­er dis­ease drug, fur­ther boost­ing reg­u­la­to­ry am­bi­tion

Last year
R&D

Japan con­sid­ers ad­just­ing clin­i­cal tri­al re­quire­ments to re­move the need for lo­cal stud­ies — re­port

Last year
Pharma
FDA+

FDA ex­plains why it de­nied about 60% of non-on­col­o­gy break­through ther­a­py re­quests from 2017 to 2019

Last year
Pharma
FDA+

Michi­gan to re­peal phar­ma in­dus­try's le­gal li­a­bil­i­ty shield from 1995

Last year
Pharma
Law

GSK rais­es rare blood can­cer aware­ness with well-known ‘Queer Eye’ de­sign­er

Last year
Pharma
Marketing

Bridge­Bio eyes US fil­ing for AT­TR-CM drug af­ter new PhI­II da­ta show ‘fastest’ clin­i­cal ben­e­fit to date

Last year
R&D

An­thos' blood thin­ner cuts the risk of bleed­ing amid race to de­vel­op safer an­ti­co­ag­u­lants

Last year
R&D

Teva's new roy­al­ty deal; Se­lec­ta merges with Carte­sian; Vir's he­pati­tis da­ta

Last year
News Briefing

Leg­end signs $100M deal with No­var­tis for next CAR-T bets, fol­low­ing up on Janssen suc­cess

Last year
Deals
Cell/Gene Tx

Aji­nomo­to to buy gene ther­a­py CD­MO Forge Bi­o­log­ics in $620M all-cash deal

Last year
Deals
Manufacturing

Neu­rode­gen­er­a­tive dis­ease-fo­cused Vec­to­rY nabs $138M to bring ALS vec­tor­ized an­ti­body to clin­ic

Last year
Financing
Startups

Aclaris los­es 85% of share val­ue af­ter an­oth­er PhII set­back in in­flam­ma­to­ry con­di­tion

Last year
R&D

UCB, Eli Lil­ly-backed Via­Nautis rais­es $25M in Se­ries A to de­vel­op ge­net­ic nanomed­i­cines

Last year
Financing
Startups

Al­ny­lam’s longer-term RNAi treat­ment low­ers blood pres­sure in mid-stage study

Last year
R&D

First da­ta for Lil­ly's RNA treat­ment for heart dis­ease point to long-term dura­bil­i­ty in tiny group of pa­tients

Last year
R&D

Verve shares first base edit­ing re­sults in hu­mans, sug­gest­ing ther­a­py can low­er cho­les­terol in pa­tients with ge­net­ic ...

Last year
R&D

Af­ter show­ing We­govy cut car­dio­vas­cu­lar risk by 20%, re­sults de­tail im­pact on death and heart fail­ure

Last year
R&D
Pharma

As­traZeneca leans in­to GLP-1; Cuts loom­ing at Bay­er; Eli Lil­ly’s obe­si­ty ap­proval; End­points Slack in­ter­view with ...

Last year
Weekly

As­traZeneca pre­pares to live with the IRA, shift­ing fo­cus of ar­gu­ments to or­phan drug changes

Last year
Pharma
Law

EMA com­mit­tee rec­om­mends ap­provals for Lil­ly's weight loss drug, Mi­rati's KRAS in­hibitor and more

Last year
Pharma
FDA+

Gilead spot­lights its on­col­o­gy work with first fo­cused brand­ing cam­paign

Last year
Pharma
Marketing

House Re­pub­li­cans threat­en to sub­poe­na FDA over Covid re­search doc­u­ments

Last year
Pharma
FDA+
First page Previous page 246247248249250251252 Next page Last page
A service from the Financial Times